Late Stage Chronic Kidney Disease Drugs Market Scope by 2031
The late stage chronic kidney disease drugs market size was estimated to be US$ 5.74 billion in 2021 and US$ XX billion in 2023 and is expected to reach US$ 17.95 billion by 2031; it is estimated to record a CAGR of 12.2% in 2023–2031. The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy are driving factors. Introducing new preclinical models to improve target validation and understand disease development will likely remain key to late stage chronic kidney disease drug market trends.
Late Stage Chronic Kidney Disease Drugs Market Analysis
The WHO has projected various strategies to support policy-makers in developing suitable policies, including the concept of the vital medicine list and the universal health coverage (UHC) approach. Moreover, European countries with advanced UHC and social protection systems have developed pharmaceutical pricing and reimbursement systems that intend to offer various crucial medicines to their citizens at no or reduced cost. Furthermore, under the ESRD PPS for CY 2024, Medicare expects to pay $6.7 billion to approximately 7,900 ESRD facilities for furnishing renal dialysis services. The final CY 2024 ESRD PPS base rate is US$271.02, an increase of US$5.45 to the current CY 2023 base rate of US$265.57.
Late Stage Chronic Kidney Disease Drugs Market Overview
Asia Pacific is the fastest-growing market for late stage chronic kidney disease drugs. The growth is mainly urged by the increasing number of ESRD patients and the growing prevalence of diabetes & hypertension (major causes of kidney failure). In Asia Pacific countries, patients with early-stage CKD progress to end-stage renal disease (ESRD), dependent on renal replacement therapy at a different rate. CKD has continued to increase among the leading causes of death worldwide because of aging and an increasing burden of risk factors for CKD, including diabetes and hypertension.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Late Stage Chronic Kidney Disease Drugs Market: Strategic Insights
Market Size Value in US$ 4,680.0 Million in 2019 Market Size Value by US$ 11,096.9 Million by 2027 Growth rate CAGR of 11.6% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Late Stage Chronic Kidney Disease Drugs Market: Strategic Insights
| Market Size Value in | US$ 4,680.0 Million in 2019 |
| Market Size Value by | US$ 11,096.9 Million by 2027 |
| Growth rate | CAGR of 11.6% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Late Stage Chronic Kidney Disease Drugs Market Drivers and Opportunities
High Prevalence of Diseases Leading to Chronic Kidney Diseases
The National Library of Medicine states that chronic kidney disease (CKD) is recognized as a leading public health problem worldwide. Globally, the estimated prevalence of CKD is 13.4%, and patients with end-stage kidney disease (ESKD) requiring renal replacement therapy are estimated to be between 4.902 and 7.083 million. Furthermore, the Centers for Disease Control and Prevention (CDC) published that in the US, More than 1 in 7 US adults, or 35.5 million people, or 14% are estimated to have CKD. Also, 9 in 10 adults with CKD are unaware of it.
Introduction of New Late Stage Chronic Kidney Disease Drugs – An Opportunity
Manufacturers are focusing on adopting strategies such as product launches and approvals, R&D investments, government funding, and partnerships to develop new drugs and provide easy access for patients worldwide. For instance, in April 2021, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to decrease the risk of declined kidney function, , cardiovascular death, kidney failure, and other problems related to chronic kidney disease who are at risk of disease progression.
The adoption of drugs has increased significantly across various North American, European, and Asian countries.
Late Stage Chronic Kidney Disease Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the late-stage chronic kidney disease drugs market analysis are product type, indication, and distribution channel.
- Based on the product type, the late stage chronic kidney disease drugs market is segmented into vitamin D, calcium-based phosphate binders, potassium binders, calcimimetics, and others. The calcimimetics segment held the largest market share in 2023, and the same segment is anticipated to register the highest CAGR during the forecast period.
- Based on indication, the late stage chronic kidney disease drug market is segmented into late stage chronic kidney disease-induced hyperparathyroidism, late stage chronic kidney disease-induced hyperphosphatemia, and late stage chronic kidney disease-induced hyperkalemia. The late stage chronic kidney disease-induced hyperparathyroidism segment held the largest market share in 2023, whereas the same segment is projected to register the highest CAGR during the forecast period.
- Based on distribution channels, the late stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest market share in 2023. However, online pharmacy is estimated to register the highest CAGR of 12.2% in the market during the forecast period.
Late Stage Chronic Kidney Disease Drugs Market Share Analysis by Geography
The geographic scope of the Late Stage Chronic Kidney Disease Drugs market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.
The North America late stage chronic kidney disease drugs market is segmented into the US, Canada, and Mexico. The US held the largest share of the North American late stage chronic kidney disease drugs market in 2023. The projected growth of the late stage chronic kidney disease drugs market in North America is the presence of key market players, growing end-stage renal disease and chronic kidney disease, and extensive R&D directed by various academic and research institutes. CKD is a major public health burden both nationally and internationally. The global mean prevalence of CKD is 13.4%, and within Canada, most recent estimates suggest at least 4 million people have the disease. CKD poses a significant burden on the healthcare system: recent estimates of healthcare costs for Canadians with CKD exceed US$40 billion annually. This condition is more common among people with hypertension, cardiovascular disease, diabetes, and others who have adverse health outcomes.
Late Stage Chronic Kidney Disease Drugs Market Report Scope
Late Stage Chronic Kidney Disease Drugs Market News and Recent Developments
The Late Stage Chronic Kidney Disease Drugs market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Late Stage Chronic Kidney Disease Drugs:
- Sun Pharma and Bayer jointly agreed to market a drug for treating chronic kidney disease. Under the terms of the agreement, Bayer has granted Sun Pharma non-exclusive rights to market and distribute a second Finerenone product under the brand name Lyvelsa. (Bayer /Press Release, January 2024)
- Boehringer Ingelheim with Eli Lilly and Company announced FDA approval for Jardiance (empagliflozin) tablets, examined as a potential treatment to reduce the risk of kidney disease development and cardiovascular death in adults with chronic kidney disease (CKD). (Source: Boehringer Ingelheim International GmbH, Press Release, October 2023)
Late Stage Chronic Kidney Disease Drugs Market Report Coverage and Deliverables
The “Late Stage Chronic Kidney Disease Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Market dynamics such as drivers, restraints, and key opportunities
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type ; Indication ; Distribution Channel , and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For